Clinical Trials on Alzheimer's Disease

LATE CALL FOR ABSTRACTS
September 1-15, 2017
www.ctad-alzheimer.com

Preliminary Program
Boston, November 1-4, 2017

www.ctad-alzheimer.com
Welcome ......................................................... p. 3
Program ................................................................. p. 4
  - Wednesday, November 1  ......................... p. 4
  - Thursday, November 2  ......................... p. 5
  - Friday, November 3  ......................... p. 8
  - Saturday, November 4  ..................... p. 10
Registration/Accommodations .......... p. 12
Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

At CTAD 2017 several teams will report the results of their preclinical, Phase II and Phase III trials. This sharing of experiences converges towards a same goal: overcoming the hurdles and speed the development of effective treatments in AD.

We look forward to welcoming you to Boston this November!
Welcome from the Organizing Committee and Presentation of the CtaD Lifetime Achievement Award to Prof. Bruno Dubois
Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner

Keynote 1
The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
Reisa Sperling, MD
Professor of Neurology, Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

Late Breaking Oral communications
8:30 – 10:00 a.m.

Coffee Break and Poster Session

OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LMI11A-31-BHS p75 neurotrophin receptor ligand.

Franti M. Lonso, MD, PhD; Manfred Windisch, PhD; Niels Andreassen, MD; Agneta Nordberg, MD, PhD

(1) Department of Neurology, and Neuromedical Sciences, Stanford University, Palo Alto, CA, USA ; (2) NeuroScics, GmbH, Graz, Austria ; (3) Department of Neurobiology, Karolinska Institute, Stockholm, Sweden ; (4) Center for Alzheimer’s Research, Karolinska Institute, Stockholm, Sweden

OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly

Bernard Hanseuwa, Beth Morrow, Alex Becher, Aaron Schultz, Jorge Sepulcre, Kathryn Papp, Heidi Jacobs, Jasmeer Chhatwal, Dorene Rentz, Reisa Sperling, and Keith Johnson

(1) Department of Radiology, Massachusetts General Hospital, Boston, MA, USA ; (2) Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium ; (3) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (4) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

OC3 - Clinical evaluation of FPI-2620, a next generation TAU PET agent in subject with Alzheimer disease and progressive supranuclear PALSY

Andrew Stephens, John Seibyl, Andre Mueller, Olivier Barret, Mathias Berndt, Jennifer Madonia, David Alagille, Hanno Schieferstein, Heiko Kroth, Santiago Bullich, Andrea Pfeifer, Andreas Muhs, Gilles Tamagnani, Kenneth Marelli, Ludger Dinkelborg

(1) Piramal Imaging, Berlin, Germany ; (2) Molecular Neuroimaging, New Haven, USA ; (3) AC Immune SA, Lausanne, Switzerland

OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Processing : The PACC 5

Kathryn V. Papp, Dorene M. Rentz, Irina Orlovsky, Reisa A. Sperling, Elizabeth C. Morrow

(1) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA ; (2) Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ; (3) Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials ? From EHR to Web-Based Cognitive Tests and e-Consent.

Peter Schueller, MD, Michael W. Weiner, MD; J. Wesson Ashford, MD, PhD, Bruno Vellas, MD, PhD

(1) UCSF, San Francisco, USA ; (2) ICON, Langer, Germany ; (3) University Duisburg-Essen, Germany ; (4) Stanford/VA Alzheimer’s Disease and Aging Clinical Research Centers, CA, USA ; (5) VA Palo Alto Health Care System, CA, USA ; (6) Stanford University, CA, USA

(1) University Hospital’s Department of Internal Medicine and Clinical Gerontology, Toulouse, France ; (2) Toulouse Gerontologie, Toulouse, France

OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: a Missing Piece of the Alzheimer’s Puzzle

Jeffrey Cummings, MD

(1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada ; (2) University of Toulouse, Toulouse, France ; (3) VU University Medical Center, Amsterdam, Netherlands ; (4) The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden (5) Alzheon, Inc., Boston, MA, USA

OC7 - ABBV-BE12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

Kumar Bugduri, Hana Florian, Deli Wang, Weinig Robieson, Holly Soares, Joel B. Braunstein, David M. Holtzman, Petr Kocis

(1) Abbott/Vale Inc, North Chicago, IL, USA ; (2) C2N Diagnostics LLC, Saint Louis, MO, USA ; (3) Washington University, St. Louis, MO, USA ; (4) NeuroRx, Cambridge, MA, USA

(1) Abbott Deutschland Gmbh & Co. KG, Ludwigshofen, Germany

OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring

Maryam Shoai, PhD; Richard Pither, PhD; Valentina Escott-Price, PhD; Simon M Laws, PhD; Harald Hampel, MD, PhD; Simone Lista, PhD; Rik Vandenberghe, Isabelle Cleynen, David Irwin, MD, Vivian Van Deerlin, MD, Greg Davidson, PhD; Virginia M.-Y. Lee, PhD; John Q. Trojanowski, MD, PhD; John Hardy, PhD, DSc

(1) UCL Institute of Neurology, London, United Kingdom ; (2) Cyxus Ltd, UK, Oxford, United Kingdom ; (3) Cardiff University, Cardiff, United Kingdom ; (4) Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia ; (5) AAR Research Fund - UPMC Chair, Paris, France ; (6) Katholieke Universiteit Leuven, Leuven, Belgium ; (7) Hospital of the University of Pennsylvania Department of Neurology, University of Pennsylvania, Philadelphia ; (8) Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia ; (9) Ledcoun Associates, UK ; (10) Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia
OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study

Rebecca E. Amariglio PhD1,2, Rachel F. Buchley PhD2,3,5, Elizabeth C. Mormino PhD2,1, Dylan R. Kirn MPH2, Gad A. Marshall MD4,5, Keith A. Johnson MD2,3, Dorene M. Rentz PsyD1,2, Reisa A. Sperling MD2,3

(1) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA ; (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (3) Harvard Medical School, Boston, MA USA ; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia ; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program : Evaluating CNP520 Efficacy in Preclinical Alzheimer’s Disease

Cristina Lopez Lopez, MD, PhD1, Pierre N. Tariot, MD2, Angelilha Caputo, PhD1, Fonda Liu, Pharm.D1, Marie-Emmanuelle Riviere, PhD1, Marie-Laure Rouzade-Dominguez, PhD1, Ronald G. Thomas, PhD1, Jessica B. Langbaum, PhD1, Rob Lenz, MD, PhD1, Eric M. Reiman, MD, PhD1, Ana Graf, MD1

(1) Novartis Pharma, Basel, Switzerland ; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA ; (3) University of California-San Diego, San Diego, CA, USA ; (4) Amgen, Thousand Oaks, CA, USA.

CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials

Moderator :  Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA

Fabian Model Ph.D.
Roche, Basel Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

Syndrome 1
11:30 – 12:30 p.m.
CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials

Moderator :  Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA

Fabian Model Ph.D.
Roche, Basel Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

Lunch and Poster Session
12:30 – 1:30 p.m.

OC11 - A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies : Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer’s Disease.

Adam Boxer, MD, PhD1; Zachary Miller, MD1, Richard Tsai, MD, MBA1, Mary Koestler, RN, PhD1; Julio Rojas, MD, PhD1; Peter Ljubembrov, MD1; Howie Rosen, MD1; Gil Rabinovici, MD1; Anne Fagan-Niven, PhD1; Yann Cobigo, PhD1; June Jung, PhD1; Phi Luong, BS1; Emmeline Chuu, BA1; Ryan Powers, BA1; Paige Mumford, BA1; Bruce Miller, MD1, Erik Roberson, MD, PhD1

(1) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA ; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA ; (3) Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA

OC12 - High dose B Vitamin therapy selectively improves cognitive function indicative of cerebrovascular status in the randomized FAVORIT Ancillary Cognitive Trial

Tammy M. Scott1, Aron M. Troen1, Irwin H. Rosenberg2

(1) Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA ; (2) Friedman School of Nutrition Science and Policy, Tufts University, Boston MA ; (3) Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel
Thursday, November 2

OC13 - Investigational New Alzheimer’s Drug Tricaprilin: Results of a Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease Patients
Samuel Henderson, PhD¹, Michael Gold, MD², Judith Walter, MD¹, Sabrina Greer¹, Janet Vogel¹, Aaron Shentin¹
(¹) Accera Inc, Boulder, CO, USA ; (²) PPD Inc, Wilmington, NC, USA

OC14 - Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab’s unique mechanism of action
William J. Meilandt¹, Janice A. Maloney¹, Jose Imperio¹, Travis W. Bainbridge², Milte Reichelt³, Danielle Mandichian⁴, Yanmei Lu⁴, James A. Ernst², Reina N. Fuji³, Jasvinder K. Atwal¹
(¹) Department of Neuroscience, Genentech, South San Francisco, CA, USA ; (²) Department of Protein Sciences, Genentech, South San Francisco, CA, USA ; (³) Department of Chemical and Translational Pharmacology, Genentech, South San Francisco, CA, USA ; (⁴) Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA ; (⁵) Department of Safety Assessment, Genentech, South San Francisco, CA, USA

2:30 – 3:00 p.m. Keynote 2
From Academy to Industry: Perspectives for Drug Trials in AD
Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience,
F. Hoffmann-La Roche, Basel, Switzerland

3:00 – 4:00 p.m. Late Breaking Oral Communications

4:00 – 4:30 p.m. Coffee Break and Poster Session

4:30 – 5:30 p.m. Symposium 2
EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease
Michael Egan, MD¹, James Kost, PhD¹, Pierre N. Tariot, MD², Paul S Aisen, MD³, Jeffrey L. Cummings, MD, ScD⁴, Bruno Vellas, MD, PhD⁴, Yukih Muhati, MD, Tiffini Voss, MD, Christine Furtelh, MS⁵, Erin Mahoney, MS, Rilt Vandenberghe, MD, PhD⁶, Yi Mo, PhD⁶, David Michelson, MD⁶
(¹) Merck & Co., Inc, Kenilworth, NJ, USA ; (²) Banner Alzheimer’s Institute, Phoenix, AZ, USA ; (³) University of Southern California, San Diego, CA, USA ; (⁴) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA ; (⁵) Gerontopole, INSERM U1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France ; (⁶) University Hospital of Leuven, Leuven, Belgium
Friday, November 3

08:30 – 10:00 a.m. Oral Communications

**OC15** - Long-Term Cognitive Decline in Patients with Alzheimer’s Disease in Association with Treatment with Cholinesterase inhibitors-data from SveDem, the Swedish Dementia Registry

Maria Erlebsdotter MD, PhD 1,2, Sara Garcia-Pracech MD, PhD 1,2, Ingemar Kåreholt PhD 1,2, Dorota Religa MD, PhD 1,2, Peter Nordström MD, PhD 1, Bengt Winblad MD, PhD 1,2.

(1) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden; (2) Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden; (3) Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden; (4) Institute of Gerontology, School of Health and Wellness, Åland University, Ålandspingen, Sweden. (5) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogenetics, Karolinska Institutet, Huddinge, Sweden; (6) Department of Community Medicine and Rehabilitation, Karolinska University, Huddinge, Sweden.

**OC16** - Selection of Amyloid Positive Pre-Symptomatic Subjects using Automatic Analysis of Neuropsychological and MRI Data for Cost-Effective inclusion Procedures in Clinical Trials

Marc Ansat, MSc 1, Stéphane Epelbaum, MD, PhD 1,2,3, Olivier Colliot, PhD 1,2, Didier Dormont, MD 2, Bruno Dubois, Prof., MD 1, Harald Hampel, Prof., MD, PhD 1,5,7, Bengt Winblad MD, PhD 1,5, for the ADNI, and the INSIGHT study group

Barcelona, Spain; (3) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (4) NeuroCog Trials, Durham, NC, USA

**OC17** - Physical Activity and Longitudinal Cognition: Results from the Harvard Aging Brain Study

Hannah M. Klein 1, Dylan R. Kirn, MPH 1, Aaron P. Schultz, PhD 1, Jennifer S. Rabin, PhD 3,4, Rachel Buckley, PhD 1,3,5,6,

(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (2) Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; (3) Harvard Medical School, Boston, MA, USA; (4) Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; (5) Florey Institutes of Neurosciences and Mental Health, Melbourne, Australia; (6) Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia

**OC18** - Validation of Tau PET Imaging in Alzheimer’s Disease and Other Tauopathies

Niljke Mattsson, MD, PhD 1,2, Michael Schöll MD, PhD 1, Tomas Ohlsson MD, PhD 1, Andreas Hahn MD, PhD 1,2, Olof Strandberg MD, PhD 1,2, Michael Schöll MD, PhD 1,2, Tomas Ohlsson MD, PhD 1, Andreas Hahn MD, PhD 1,2, Olof Strandberg MD, PhD 1,2.

(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (2) Department of Clinical Sciences, Malmö, Lund University, Sweden; (3) Department of Radiation Physics, Södertörn University Hospital, Lund, Sweden; (4) Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; (5) Department of Clinical Physiology and Nuclear Medicine, Södertörn University Hospital, Lund, Sweden.

**OC19** - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update

Kathleen A. Welsh-Bohmer, PhD 1, Brenda L. Plassman, PhD 1, Carl Chiang, PhD 2, Meredith Culp, BS 3, Patrick Harrigan, OC19 - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update

(1) Department of Psychiatry & Neurology, Duke University, Durham NC, USA; (2) Zinfandel Pharmaceuticals, Inc., Chapel Hill NC, USA; (3) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (4) NeuroCog Trials, Durham, NC, USA

**OC20** - Emerging Plasma-Based Therapies for AD

Montserrat Costa PhD 1, Raquel Hornillo PhD 1, Ana M Ortiz MSc 1, Alba Pérez PhD 1, Laura Núñez BSc 2, Antonio Páez MSc 1, Mercedes Bode MD 1, Agusín Ruiz MD, PhD 1, Salvador Grancha PhD 1

(1) Research & Development, Grifols Bioscience Industrial Group, Parets del Vallès, Spain; (2) Clinical Operations Department. Grifols Bioscience Industrial Group, Sant Cugat del Vallès, Spain; (3) Memory Clinic of Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain

10:00 – 10:30 a.m. Coffee Break and Poster Session

10:30 – 11:00 a.m. Keynote 3

**OC21** - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials

Andrew J. Aschenbrenner, PhD, Jason Hassenstab, PhD, Eric McDade, DO, Quocqiao Wang, PhD, Tammie L.S. Bengtzer, MD, PhD, Randall J. Bateman, MD, & John C. Morris, MD.

(1) Department of Neurology, Washington University in St. Louis; (2) Department of Psychological and Brain Sciences, Washington University in St. Louis; (3) Department of Biostatistics, Washington University in St. Louis; (4) Department of Radiology, Washington University in St. Louis

**OC22** - Emerging Plasma-Based Therapies for AD

Montserrat Costa PhD 1, Raquel Hornillo PhD 1, Ana M Ortiz MSc 1, Alba Pérez PhD 1, Laura Núñez BSc 2, Antonio Páez MSc 1, Mercedes Bode MD 1, Agusín Ruiz MD, PhD 1, Salvador Grancha PhD 1

(1) Research & Development, Grifols Bioscience Industrial Group, Parets del Vallès, Spain; (2) Clinical Operations Department. Grifols Bioscience Industrial Group, Sant Cugat del Vallès, Spain; (3) Memory Clinic of Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain

11:00 – 12:30 p.m. Oral Communications

**OC21** - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials

Andrew J. Aschenbrenner, PhD, Jason Hassenstab, PhD, Eric McDade, DO, Guoqiao Wang, PhD, Tammie L.S. Bengtzer, MD, PhD, Randall J. Bateman, MD, & John C. Morris, MD.

(1) Department of Neurology, Washington University in St. Louis; (2) Department of Psychological and Brain Sciences, Washington University in St. Louis; (3) Department of Biostatistics, Washington University in St. Louis; (4) Department of Radiology, Washington University in St. Louis
OC22 - Eigen Combinations of Cognition and Biomarkers to Minimize the Sample Sizes in Prevention Trials on Alzheimer Disease
Chengjie Xiong1,2,3,4, PhD, Anne M. Fagan2,3, PhD, Tammie Benzinger7,5,6, PhD, Jason Hassenstab7,5,6, PhD, John C. Morris2,3,4, MD, Randall J. Bateman5,6, MD
(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA; (2) Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; (4) Department of Mathematics, Washington University, St. Louis, MO, USA; (5) Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA

OC23 - The Alzheimer’s Prevention Registry and GeneMatch: Accelerating Recruitment and Enrollment into Alzheimer’s Studies
Jessica B. Langbaum, PhD1; Nellie High1; David Gordon1; Jodie Nichols1; Trisha Walsh1; Eric M. Reiman2; MD, Pierre N. Tariot1; MD
(1) Banner Alzheimer’s Institute, Phoenix, AZ, USA

OC24 - An Examination of Rate of Decline as an Alternative to Change from Baseline
Howard Machey, PhD1; Nan Hu, PhD; Michael Ahmadi, MSc2; Yinhua Chen, MSc2; Pierre Tariot, MD1; Eric M Reiman, MD1; Francisco Lopera, MD1; Kewei Chen, PhD2; Ronald Thomas, PhD2
(1) Genentech, Inc, South San Francisco, CA, USA; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA

OC25 - The Safety and Efficacy of Edonerpic (T-817) in Patients with Mild to moderate Alzheimer’s Disease
Lon S. Schneider, MD,1 Ronald G. Thomas, PhD,2 James Brewer, MD,2 Suzanne Hendrix, PhD2, Robert Rissman, PhD2, David Salmon, PhD,2 Hiroshi Kobayashi,2 Howard Feldman, MD,2 for the ADCS TCAD group
(1) Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; (2) University of California, San Diego, CA, USA

OC26 - Safety of and Tolerability of Gantenerumab in the Open-Label Extension of SCarlet RoAD Trial, a Global Study in Patients with Prodromal Disease
Mirjana Andjelkovic, PhD1; Danielle Abi-Saab, Psy.D 1; Nathalie Pross, PhD1; Paul Delmar, PhD1; Nicola Voyle, PhD1; Michaela Mertes1; Smiljana Ristic, MD1
(1) Hoffman LaRoche, Basel, Switzerland; (2) Roche Products Limited, Welwyn, UK

Moderator: Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. Role of 5-HT2a Receptors in the Pharmacology of Alzheimer’s disease Psychosis
Stephen M. Stahl, MD, PhD, Ethan S. Burstein, PhD
(1) University of California, San Diego, CA, USA; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis
Clive Ballard, MBChB, MRCPSych1; Carol Banister, MBChB, MRCPSych1; Jim Youakim, MD1; Bruce Coate, MPH1; Srdjan Stankovic, MD, MSPH1, on behalf of the ADP Investigators
(1) University of Exeter Medical School, Exeter, UK; (2) King’s College, London, UK; (3) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials
Pierre N. Tariot, MD1; Randall Owen, MD1; Doral Fredericks, PharmD, MBA2
(1) Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA
Friday, November 3

3:30 – 4:00 p.m. Oral Communications

**OC27** - The European Prevention of Alzheimer’s Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer’s Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.

Andrew Satlin, MD¹, Craig Ritchie MD PhD², Miia Kivipelto MD PhD², Alina Soloman MD PhD², Brian Tom PhD⁴, Jose Luis Molinuevo MD PhD⁴, Scott Berry PhD⁴, Frederik Barkhof MD PhD⁴, Gill Farrar PhD⁴

¹Eisai Pharmaceuticals, USA (2) Centre for Dementia Prevention, University of Edinburgh, UK (3) Ageing Research Centre, Karolinska Institute, Sweden (a) MRC Biostatistics Unit, University of Cambridge, UK (5) Barcelona Beta Brain Research Centre, Spain (6) Berry Consultants Ltd, Texas, USA (7) VU University Medical Centre, Amsterdam, The Netherlands (8) General Electric, Amersham, UK

**OC28** - Towards a New Biomarker Battery for Drug Development in Alzheimer’s Disease

Olivier Blin, MD, PhD¹, Régis Bordet MD PhD², Jill Richardson PhD³, Pierre Payoux MD PhD³, Claudio Babiloni MD PhD⁵, David Bartrés-Faz MD PhD⁶, Catherine Cassé-Perot PhD⁶, Giovanni Frisoni MD PhD⁷

¹University of Aix-Marseille (2) University of Lille (3) GSK (4) University of Toulouse (5) University of Roma (6) University of Barcelona (7) University of Geneva

4:00 – 4:30 p.m. Coffee Break and Poster Session

4:30 – 5:00 p.m. Keynote 4

Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ - USA

5:00 – 6:00 p.m. Symposium 4

Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepirdine in Mild-to-Moderate Alzheimer’s Disease

• Presentation 1: Analysis of primary efficacy and safety results
• Presentation 2: Analysis of secondary endpoints and measures of clinical meaningfulness
• Discussion and Q&A
Coffee Break and Poster Session

10:00 – 11:30 a.m.

Late Breaking Oral Communications

11:30 – 12:30 p.m.

Symposium 5

Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities

Moderator: Arjen Brussard, PhD, Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration
   Giovanna Mallucci, MD PhD2
   (1) Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK ; (2) UK Dementia Research Institute, Cambridge, UK

2. Modulation of synaptic and network activity and endocytosis with light flicker therapy reduces amyloid pathology in mouse model of AD
   Li-Hueh Tsai, PhD1
   (1) Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge MA, USA

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction
   John Alam, MD1
   (1) Eli Lilly and Company, Indianapolis, IN, USA ; (2) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA ; Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)
Lunch and Poster Presentation

Clinical Trials Prescreening Focus Panel: Prescreening Initiatives to Identify Individuals with Preclinical or Early Alzheimer’s Disease for Clinical Trials

Moderator: Jamie A Mullen, MD, AstraZeneca, Waltham MA, USA

1. The Funnel study: Prescreening for MCI and mild AD patients from the CHARIOT Register
Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, UK

2. A prescreening study using amyloid PET to improve recruitment for early Alzheimer’s disease drug trials
Christopher C Rowe, MD Austin Health, Melbourne, Australia

3. Models of Patient Engagement in Alzheimer’s Disease (MOPEAD): a European project to move Alzheimer’s disease environment towards an earlier diagnosis
Mercè Boada, MD, PhD; Laura Campoz; Dhaal Diesal; Hans Peter Hunderemer; Octavio Rodriguez-Gomez, MD; Bengt Winblad, Prof, MD, PhD; Frant Jessen, MD, PhD; Peter Jelle Visser, MD, PhD; Milica Kraberger, MD, PhD; Rafael Simo, MD, PhD; Rafael Navajo; Annette Dumas; Jean Georges, BA; David Krivec; Peggy Maguire; Derech Mackenzie
(1) Fundació ACE. Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; (2) Eli Lilly and Company Ltd, Basingstoke, United Kingdom; (3) AstraZeneca AB, Soderatne, Sweden; (4) Lilly Deutschland GmbH, Bad Homburg, Germany; (5) Karolinska Institutet, Center On Alzheimer Research, Div of Neuroepidemiology, Huddinge, Sweden; (6) German Centre for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany; (7) Stichting VUmc, Amsterdam, Netherlands; (8) University Medical Centre Ljubljana, Ljubljana, Slovenia; (9) Institut de Recerca Hospital Universitari Vell d’Hebron (VH), Barcelona, Spain; (10) GMV Soluciones Globales Internets S.A.L, Barcelona, Spain; (11) AGM Consulting, Auderghem, Belgium; (12) Alzheimer Europe, Luxembourg, Luxembourg; (13) Spomincsa – Alzheimer Slovenia, Ljubljana, Slovenia; (14) European Institute of Women’s Health, Dublin, Ireland; (15) KITE Innovation (Europe) Ltd, Huddersfield, United Kingdom

4:15 – 4:30 p.m. Closing Session

2:15 – 3:15 p.m. Oral Communications

Jason Hassenstab, PhD1,2,3,4, Andrew J. Aschenbrenner, PhD1,3,4, Martin J. Sliwinski, PhD4, Eric McDade, DO1,3,4, Yen Ying Lim, PhD5, Paul Maruff, PhD6,7, David A. Balota, PhD1,2,4, John C. Morris, MD1,4, Randall J. Bateman, MD1,4, & The Dominantly Inherited Alzheimer Network-Trials Unit.
(1) Department of Neurology, Washington University School of Medicine, St. Louis, MO USA; (2) Department of Psychological & Brain Sciences, Washington University in St. Louis, St. Louis, MO USA; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), Washington University School of Medicine, St. Louis, MO USA; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO USA; (5) Department of Human Development and Family Studies, Pennsylvania State University, State College, PA USA; (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia; (7) Cogstate Ltd, Melbourne, Victoria, Australia

OC36 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloid
Sarah J Carr PhD1, Judith Jaeger PhD2,3, Nancy Maserejian ScD4, Ahmed Enayatallah4, Alan Lerner5, Yanming Wang6, Sheng Yang7, Wenting Wang7, Shijia Biang4, Curtis Tatsuoka PhD1,5 and for the Alzheimer’s Disease Neuroimaging Initiative*
(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) CognitionMetrics, DE USA; (3) Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA; (4) Biogen, Cambridge, MA, USA; (5) Neurological Institute, University Hospitals Case Medical Center, Beachwood, OH USA; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

OC37 - Alzheimer’s Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from GERAS
Catherine Reed, PhD1, Mark Belger, BSc1, J. Scott Andrews, PharmD2, Anjite Tochthorn-Heidenreich, MSc1.
(1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly and Company, Indianapolis, IN, USA

OC38 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25-35 Peptide-Induced Toxicity in Mice.
Guillaume J. Blivet, MS1, Johann Meunier, PhD2, Francois J. Roman, PhD3,4, Jacques Touchon, MD, PhD3,4
(1) REGEN-JIEF SAS, Montepeller, France; (2) Amylegen SAS, Montferrier-sur-Lez, France; (3) INSERM U1061, Montpellier, France; (4) University of Montpellier, France
Early bird fees (until September 1)

1. Regular Registration (no lunches) 895€ - Regular registration (with 3 lunches) 1024€
2. EADC Member registration (no lunches) 704€ - Regular registration (with 3 lunches) 833€
(to benefit from this rate you must be an active member of the European Disease Consortium)

Full registration fees (After September 2)

1. Regular Registration (no lunches) 1027€ - Regular registration (with 3 lunches) 1156€
2. EADC Member registration (no lunches) 854€ - EADC Member registration (with 3 lunches) 983€
(to benefit from this rate you must be an active member of the European Disease Consortium)

Please note that registration to CTAD 2017 includes:
- access to all conference sessions, attendee bag, one-year online subscription to the Journal of Prevention of Alzheimer’s Disease (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

ACCOMMODATIONS

Book your accommodation at the Conference Venue

This year again CTAD has negotiated a special price to stay at the Boston Park Plaza where CTAD will be held.

Boston Park Plaza
50 Park Plaza at Arlington Street
Boston, MA 02116-3912

- The price for a single room is 279$ (including breakfast)
- The price for a double room is 319$ (including breakfast for 2 people)

Make sure your book your room early on to ensure you stay at the conference venue.

Book your room on our website www.ctad-alzheimer.com
Get in touch

CTAD BOSTON 2017
CTAD Congress
Phone: +33 4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTAD2017
CTAD Alzheimer
CTAD Conference

#CTAD2017

www.ctad-alzheimer.com